Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is�…

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this�…

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American�…

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of�…

Background: In 2002 the American Thoracic Society/European Respiratory Society
(ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific�…

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American�…

Little is known about the relative importance of monocyte and tissue-resident macrophages
in the development of lung fibrosis. We show that specific genetic deletion of monocyte�…

Background A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has
been widely used as a treatment for idiopathic pulmonary fibrosis. The safety and efficacy of�…

Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial
pneumonia, is a progressive, irreversible, and typically lethal disease characterized by an�…

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some�…